News

Title
infusion medication on IV
More on the Rx Front: The slow emergence in the U.S. of biosimilars for curbing specialty costs
Apr 27

Last month we highlighted how both cost and utilization are increasing when it comes to prescription drugs. Much of the increase is due to the rise in specialty medications. This trend is national, across all industries, and continues to be of great concern. The rising costs of medications result in potential barriers for patients’ ability to afford and/or access the drugs they need to be as well as possible.

Related to the surge in specialty medications—which often means patients receiving very expensive yet effective, life-altering biologic therapies—it’s helpful to know about the biosimilars that are emerging slowly on the market.

Here is some background on this valuable drug product option, which you can expect to read more about in the coming months and years.

Defining biosimilars
The Public Health Safety Act defines biosimilarity to mean, “The biological product is highly similar to the reference product not withstanding minor differences in clinically inactive components and . . . there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity, and potency of the product.” 

The goal of biosimilars is to provide additional, more cost-effective options for patients. At a very high level, biosimilars may be able to bring greater accessibility and affordability to the market for these complex conditions that require biologics to be treated effectively.

What biosimilars are on the market today?
To date, there are 35 biosimilars available in the United States. You will find FDA-approved biosimilars for popular specialty drugs like Humira, Enbrel, and Remicade—which treat autoimmune conditions like Crohn’s or Rheumatoid Arthritis. There are also biosimilars for diabetes, certain cancer drugs, eye conditions, and more.


The simplest way to think about biosimilars is by considering them almost generics for biologics. Biologics aren’t easy to imitate, as living cells are unique. GoodRx notes that biosimilars are like biologics in their structure, function, safety, and effectiveness. They are not, however, the same as the actual biologic medication. As its name suggests, they are similar to their respective biologic in terms of safety and effectiveness. The Research Advocacy Network, in its Introduction to Biosimilars Medicine downloadable resource, clearly illustrates the key differences between biologics and biosimilars in this graphic:

 

FDA requirements for biosimilars
The FDA requires that differences be minor in clinically inactive components and there is no meaningful difference in terms of safety and effectiveness. You can read more about the FDA’s biosimilar guidelines here.

When to expect new biosimilars on the market
As brand-name biologics reach the end of their exclusivity rights, that’s when biosimilars start coming into play. While it takes time to get biosimilars on the market, it can take less time and cost less than when new biologics enter the market.
 

Savings potential with biosimilars
Despite the number of biosimilars entering the market slowly, the savings opportunities are great. The RAND Corporation, a nonprofit research organization that develops solutions to public policy challenges to help make communities throughout the world safer and more secure, healthier and more prosperous, published an extensive study in 2018 that estimated biosimilars will reduce direct spending on biologic drugs by $54 billion from 2017 to 2026, or about 3 percent of total estimated biologic spending over the same period, with a range of $24 to $150 billion.

In January 2022, The American Journal of Managed Care® (AJMC) released their research and findings of potential savings related to biosimilars. The ACMC projects that biosimilars will lower spending on biologics by $38.4 billion from 2021 to 2025, with the bulk of savings accruing from new downward pressure on reference brand-name biologic prices and from new biosimilar entry.

What’s next
It is our hope, and many others, that the many players in the making and distributing of biosimilars can come together and offer them as a true, lower cost yet effective and safe alternative to their inspired biologics.

Three interesting reads on biosimilars

Read our October Update with Guest Post about the Cost of Musculoskeletal Conditions, Shareable Content for Employees, and More

Oct 31
Read our October Update with Guest Post about the Cost of Musculoskeletal Conditions, Shareable Content for Employees, and More

Inside our October 2022 newsletter, you'll read about:Our November 2 virtual and free Thought Leadership Series with Human Resources leader Megan NailThe Cos...

Continue Reading

edHEALTH President and CEO featured in Global Captive Podcast

Sep 6
GCP image for interview about edHEALTH

Hear from edHEALTH President and CEO Tracy Hassett as she was interviewed with Spring Consulting’s Managing Partner Karin Landry in a recent GCP Short. In th...

Continue Reading

Planning for Your 2023 Annual Open Enrollment: 4 Strategies to Consider for Greater Success

Sep 26
3 women talking at conference table (photo by Photo by Yan Krukov)

Photo by Yan KrukovSince the pandemic, most employers have seen significant shifts in how to manage open enrollment periods. From big fairs onsite to virtual...

Continue Reading

What are Biosimilars? Learn more about this emerging Rx trend and more in edHEALTH's April newsletter.

May 3
Image of tablet or mobile phone with in-box highlighted

Read about: The emergence of biosimilars for curbing specialty costsGearing up for edHEALTH's 5th annual Walking ChallengeNews and tips for spring health and...

Continue Reading

Understanding the value and costs of cell and gene therapy

Jun 30
Photo by National Cancer Institute

Understanding the value and costs of cell and gene therapyInnovation in health care is constant and is marked often by significant breakthrough treatments an...

Continue Reading

Supporting mental health awareness in the workplace should be year-round: Tips to help employers and more in our May newsletter

May 31
Mental health matters (image of ipad)

In our most recent newsletter, you'll learn:Why workplaces should support employees with mental health awareness year-roundHow telehealth continues to be an ...

Continue Reading

Discover summer safety tips to share, the value and cost of cell and gene therapy, and edHEALTH annual meeting news

Jun 30
cell and gene theapy

In our summer newsletter, you'll findAn overview of the value and cost of cell and gene therapyShare-it downloads for promoting summer safety among employees...

Continue Reading

What do consumers think about their employer-provided health coverage during the COVID-19 pandemic?

Jul 28
Doctor with phone for telehealth call

It’s a question that America's Health Insurance Plans (AHIP) asked in a recent survey that the Locust Street Group completed on behalf of AHIP Coverage@Work....

Continue Reading

Share-it Employee Engagement Communications

Sep 22
edHEALTH employee engagement share-it communications

edHEALTH provides share-it employee engagement communications to help member school employees navigate and maximize their healthcare benefits. Check out thes...

Continue Reading

edHEALTH President & CEO Talks Advanced Medical Stop Loss at VCIA on August 11, 2022

Aug 9
Tracy Hassett speaks at VCIA on 8-11-22

Want to learn more about Captive Insurance? Join edHEALTH's President & CEO, Tracy Hassett, along with other industry leaders, talks about medical stop l...

Continue Reading

Sign up for our free Thought Leadership Series on November 2, read tips for a successful open enrollment and more

Oct 17
Megan Nail - thought leadership webinar on 11/2/22

In our September newsletter, you'll discover:How to sign up for our free virtual Thought Leadership Series on November 2 with industry leader Megan Nail4 str...

Continue Reading

Tracy Hassett, edHEALTH's President and CEO elected as the new Board Chair

Oct 27
Tracy Hassett edHEALTH President & CEO

Great news for the Vermont Captive Insurance Association (VCIA), as they've selected edHEALTH President & CEO to be their new Board Chair. The VCIA, one ...

Continue Reading
Top shadow

Contact Us

866.692.7473

Contact edHEALTH today for more information.